These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 16406743)

  • 21. Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: preliminary report.
    Maschio M; Dinapoli L; Saveriano F; Pompili A; Carapella CM; Vidiri A; Jandolo B
    Acta Neurol Scand; 2009 Sep; 120(3):210-2. PubMed ID: 19719809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zonisamide: newer antiepileptic agent with multiple mechanisms of action.
    Biton V
    Expert Rev Neurother; 2004 Nov; 4(6):935-43. PubMed ID: 15853520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy.
    Marinas A; Villanueva V; Giráldez BG; Molins A; Salas-Puig J; Serratosa JM
    Epileptic Disord; 2009 Mar; 11(1):61-6. PubMed ID: 19264587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy.
    Guerrini R; Rosati A; Segieth J; Pellacani S; Bradshaw K; Giorgi L
    Epilepsia; 2013 Aug; 54(8):1473-80. PubMed ID: 23837461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management and monitoring of patients treated with zonisamide: the OZONE study.
    Dupont S; Biraben A; Lavernhe G; Marquet T; Allaf B
    Epileptic Disord; 2013 Sep; 15(3):278-88. PubMed ID: 23906691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zonisamide: pharmacokinetics, efficacy, and adverse events in children with epilepsy.
    Wallander KM; Ohman I; Dahlin M
    Neuropediatrics; 2014 Dec; 45(6):362-70. PubMed ID: 25133701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures.
    Faught E
    Seizure; 2004 Dec; 13 Suppl 1():S59-65; discussion S71-2. PubMed ID: 15511695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy.
    Kothare SV; Kaleyias J; Mostofi N; Valencia I; Melvin JJ; Hobdell E; Khurana DS; Legido A
    Pediatr Neurol; 2006 May; 34(5):351-4. PubMed ID: 16647993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flexible dosing of adjunctive zonisamide in the treatment of adult partial-onset seizures: a non-comparative, open-label study (ZEUS).
    Dupont S; Striano S; Trinka E; Springub J; Giallonardo AT; Smith P; Ellis S; Yeates A; Baker G
    Acta Neurol Scand; 2010 Mar; 121(3):141-8. PubMed ID: 20047564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial.
    Guerrini R; Rosati A; Bradshaw K; Giorgi L
    Epilepsia; 2014 Apr; 55(4):568-78. PubMed ID: 24621319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levetiracetam: a long-term follow-up study of efficacy and safety.
    Bauer J; Ben-Menachem E; Krämer G; Fryze W; Da Silva S; Kasteleijn-Nolst Trenité DG
    Acta Neurol Scand; 2006 Sep; 114(3):169-76. PubMed ID: 16911344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study.
    Vossler DG; Conry JA; Murphy JV;
    Epileptic Disord; 2008 Mar; 10(1):31-4. PubMed ID: 18367429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential efficacy of zonisamide in refractory juvenile myoclonic epilepsy: retrospective evidence from an Irish compassionate-use case series.
    O'Rourke D; Flynn C; White M; Doherty C; Delanty N
    Ir Med J; 2007 Apr; 100(4):431-3. PubMed ID: 17566478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zonisamide: its pharmacology, efficacy and safety in clinical trials.
    Brodie MJ; Ben-Menachem E; Chouette I; Giorgi L
    Acta Neurol Scand Suppl; 2012; (194):19-28. PubMed ID: 23106522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience.
    Kluger G; Kurlemann G; Haberlandt E; Ernst JP; Runge U; Schneider F; Makowski C; Boor R; Bast T
    Epilepsy Behav; 2009 Mar; 14(3):491-5. PubMed ID: 19162229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term effects of zonisamide in the treatment of epilepsy in children with intellectual disability.
    Iinuma K; Minami T; Cho K; Kajii N; Tachi N
    J Intellect Disabil Res; 1998 Dec; 42 Suppl 1():68-73. PubMed ID: 10030436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
    Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
    Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zonisamide: new drug. No advantage in refractory partial epilepsy.
    Prescrire Int; 2007 Jun; 16(89):95-7. PubMed ID: 17582922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy.
    Pieribone VA; Tsai J; Soufflet C; Rey E; Shaw K; Giller E; Dulac O
    Epilepsia; 2007 Oct; 48(10):1870-4. PubMed ID: 17634060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety profile of levetiracetam.
    Arroyo S; Crawford P
    Epileptic Disord; 2003 May; 5 Suppl 1():S57-63. PubMed ID: 12915343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.